The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis

Abstract Background Adalimumab is an anti‐tumour necrosis factor administered for the management of severe psoriasis. Previously limited to Humira, new biosimilar medications have now emerged including Amgevita. To date, there have been no comparison studies of adalimumab biosimilar use on different...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Panahi, Y. Skelly, R. Zaman
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/8118a780452344d4b8f073e5a754a5b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8118a780452344d4b8f073e5a754a5b2
record_format	dspace
spelling	oai:doaj.org-article:8118a780452344d4b8f073e5a754a5b22021-12-02T11:13:08ZThe effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis2690-442X10.1002/ski2.60https://doaj.org/article/8118a780452344d4b8f073e5a754a5b22021-12-01T00:00:00Zhttps://doi.org/10.1002/ski2.60https://doaj.org/toc/2690-442XAbstract Background Adalimumab is an anti‐tumour necrosis factor administered for the management of severe psoriasis. Previously limited to Humira, new biosimilar medications have now emerged including Amgevita. To date, there have been no comparison studies of adalimumab biosimilar use on different types of psoriasis. Objective To investigate the implications of biosimilar medications and patient specific factors on clinical outcomes, including Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores. Methods A clinical notes review was performed for all dermatology patients with adalimumab‐controlled psoriasis at our centre. Demographic profile, psoriasis subtype and changes in clinical patterns as demonstrated by PASI and DLQI were extracted and analysed. Results Of 91 records identified, 70 patients met the inclusion criteria. 21 patients (30%) demonstrated significant increase in PASI and DLQI scores with Amgevita. Scores improved to baseline once Humira was restarted. Findings reveal no difference in pre‐adalimumab disease severity or mean age between the groups. Patients responding only to Humira had a greater proportion of females, and were likelier to have psoriatic arthritis (odds ratio [OR]: 10.63; p < 0.0002) and nail involvement (OR: 6.13, p < 0.02), compared with patients well controlled with Amgevita. Conclusions This audit of a single dermatology centre suggests switching to a biosimilar adalimumab may exacerbate symptoms of psoriasis. Future studies should investigate whether findings are restricted to our study population, and consider the influence of other factors, such as disease subtypes and medication formulations.M. PanahiY. SkellyR. ZamanWileyarticleDermatologyRL1-803ENSkin Health and Disease, Vol 1, Iss 4, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803
spellingShingle	Dermatology RL1-803 M. Panahi Y. Skelly R. Zaman The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
description	Abstract Background Adalimumab is an anti‐tumour necrosis factor administered for the management of severe psoriasis. Previously limited to Humira, new biosimilar medications have now emerged including Amgevita. To date, there have been no comparison studies of adalimumab biosimilar use on different types of psoriasis. Objective To investigate the implications of biosimilar medications and patient specific factors on clinical outcomes, including Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores. Methods A clinical notes review was performed for all dermatology patients with adalimumab‐controlled psoriasis at our centre. Demographic profile, psoriasis subtype and changes in clinical patterns as demonstrated by PASI and DLQI were extracted and analysed. Results Of 91 records identified, 70 patients met the inclusion criteria. 21 patients (30%) demonstrated significant increase in PASI and DLQI scores with Amgevita. Scores improved to baseline once Humira was restarted. Findings reveal no difference in pre‐adalimumab disease severity or mean age between the groups. Patients responding only to Humira had a greater proportion of females, and were likelier to have psoriatic arthritis (odds ratio [OR]: 10.63; p < 0.0002) and nail involvement (OR: 6.13, p < 0.02), compared with patients well controlled with Amgevita. Conclusions This audit of a single dermatology centre suggests switching to a biosimilar adalimumab may exacerbate symptoms of psoriasis. Future studies should investigate whether findings are restricted to our study population, and consider the influence of other factors, such as disease subtypes and medication formulations.
format	article
author	M. Panahi Y. Skelly R. Zaman
author_facet	M. Panahi Y. Skelly R. Zaman
author_sort	M. Panahi
title	The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
title_short	The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
title_full	The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
title_fullStr	The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
title_full_unstemmed	The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
title_sort	effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/8118a780452344d4b8f073e5a754a5b2
work_keys_str_mv	AT mpanahi theeffectofbiosimilaradministrationonclinicaloutcomesinpatientswithadalimumabcontrolledpsoriasis AT yskelly theeffectofbiosimilaradministrationonclinicaloutcomesinpatientswithadalimumabcontrolledpsoriasis AT rzaman theeffectofbiosimilaradministrationonclinicaloutcomesinpatientswithadalimumabcontrolledpsoriasis AT mpanahi effectofbiosimilaradministrationonclinicaloutcomesinpatientswithadalimumabcontrolledpsoriasis AT yskelly effectofbiosimilaradministrationonclinicaloutcomesinpatientswithadalimumabcontrolledpsoriasis AT rzaman effectofbiosimilaradministrationonclinicaloutcomesinpatientswithadalimumabcontrolledpsoriasis
_version_	1718396115601063936

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis

Ejemplares similares